Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeting Glioblastoma Cell State Plasticity for Enhanced Therapeutic Efficacy.

bioRxiv : the preprint server for biology·2025
Same author

A novel model of glioblastoma recurrence to identify therapeutic vulnerabilities.

EMBO molecular medicine·2025
Same author

Three-dimensional regulatory hubs support oncogenic programs in glioblastoma.

Molecular cell·2025
Same author

Antiretroviral drug therapy does not reduce neuroinflammation in an HIV-1 infection brain organoid model.

Journal of neuroinflammation·2025
Same author

Three-dimensional regulatory hubs support oncogenic programs in glioblastoma.

bioRxiv : the preprint server for biology·2025
Same author

Bridging the gap between tumor and disease: Innovating cancer and glioma models.

The Journal of experimental medicine·2024

Related Experiment Video

Updated: Nov 18, 2025

A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas
06:27

A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas

Published on: May 9, 2025

883

Diffuse Glioma Heterogeneity and Its Therapeutic Implications.

James G Nicholson1, Howard A Fine2

  • 1Department of Neurology, The Meyer Cancer Center, Weill Cornell Medicine, New York, New York.

Cancer Discovery
|February 9, 2021
PubMed
Summary
This summary is machine-generated.

Diffuse gliomas are lethal brain tumors with high heterogeneity, leading to treatment resistance. Targeting cellular states, not just genes, offers a new "State Selective Lethality" strategy to overcome this adaptability.

More Related Videos

Digital Spatial Profiling for Characterization of the Microenvironment in Adult-Type Diffusely Infiltrating Glioma
09:17

Digital Spatial Profiling for Characterization of the Microenvironment in Adult-Type Diffusely Infiltrating Glioma

Published on: September 13, 2022

2.5K
Author Spotlight: Enhanced Generation of Patient-Derived 3D Organoids for Glioblastoma and Glioma
05:45

Author Spotlight: Enhanced Generation of Patient-Derived 3D Organoids for Glioblastoma and Glioma

Published on: January 19, 2024

2.4K

Related Experiment Videos

Last Updated: Nov 18, 2025

A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas
06:27

A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas

Published on: May 9, 2025

883
Digital Spatial Profiling for Characterization of the Microenvironment in Adult-Type Diffusely Infiltrating Glioma
09:17

Digital Spatial Profiling for Characterization of the Microenvironment in Adult-Type Diffusely Infiltrating Glioma

Published on: September 13, 2022

2.5K
Author Spotlight: Enhanced Generation of Patient-Derived 3D Organoids for Glioblastoma and Glioma
05:45

Author Spotlight: Enhanced Generation of Patient-Derived 3D Organoids for Glioblastoma and Glioma

Published on: January 19, 2024

2.4K

Area of Science:

  • Neuro-oncology
  • Cancer Biology
  • Genetics

Background:

  • Diffuse gliomas are aggressive brain tumors with poor treatment outcomes.
  • Current therapies targeting specific genetic mutations show limited efficacy due to tumor heterogeneity.
  • Intratumoral heterogeneity (ITH) in gliomas encompasses genetic, epigenetic, and environmental factors.

Purpose of the Study:

  • To review how glioma ITH and cell state plasticity contribute to therapeutic resistance.
  • To explore novel therapeutic strategies that address the challenges posed by glioma heterogeneity.
  • To introduce the concept of "State Selective Lethality" as a potential therapeutic approach.

Main Methods:

  • Review of current literature on glioma biology, heterogeneity, and therapeutic resistance.
  • Analysis of the interplay between genetic diversity and epigenetic regulation in driving cell states.
  • Conceptualization of a novel therapeutic strategy based on targeting cell states.

Main Results:

  • Glioma ITH results in extreme cellular phenotypic heterogeneity and adaptability.
  • Malignant cell state plasticity is a key mechanism of resistance to targeted therapies.
  • Convergence of diverse glioma cells into limited epigenetic cell states offers a therapeutic vulnerability.

Conclusions:

  • Glioma ITH and cell state plasticity are major obstacles for developing effective targeted therapies.
  • "State Selective Lethality" proposes targeting epigenetically defined cell states rather than genetic mutations.
  • Cell state "trapping agents" may minimize plasticity-mediated resistance, offering a new therapeutic avenue.